Abstract
In this review, we focus on the chemicals used in the current treatment of type 2 diabetes and discuss some potentially viable, promising targets in the management of this metabolic syndrome, with a special mention to some naturally occurring bioactive compounds. Non insulin dependent diabetes mellitus (NIDDM or Type 2 diabetes) is a prevalent, chronic metabolic disorder, which affects more than 171 million people worldwide. Diminished insulin secretion due to impaired cell function and or insulin resistance of the peripheral tissues such as liver, adipose tissue and skeletal muscle causes hyperglycemia, which is controlled with suitable pharmacological agents. The current line of treatment includes: (1) insulin secretagogues, (2) insulin sensitizers, (3) dipeptidyl peptidase IV inhibitors, (4) biguanides, (5) glucosidase inhibitors and (6) drugs in development.
Keywords: Oral Hypoglycemics, metabolic syndromeNon insulin dependent diabetes mellitus (NIDDM), chronic metabolic disorder, hyperglycemia, insulin sensitizers, biguanides
Current Bioactive Compounds
Title: Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes
Volume: 4 Issue: 2
Author(s): S. W. Zito, J. Shinde, I C. S. Chen, T. Taldone and M. Barletta
Affiliation:
Keywords: Oral Hypoglycemics, metabolic syndromeNon insulin dependent diabetes mellitus (NIDDM), chronic metabolic disorder, hyperglycemia, insulin sensitizers, biguanides
Abstract: In this review, we focus on the chemicals used in the current treatment of type 2 diabetes and discuss some potentially viable, promising targets in the management of this metabolic syndrome, with a special mention to some naturally occurring bioactive compounds. Non insulin dependent diabetes mellitus (NIDDM or Type 2 diabetes) is a prevalent, chronic metabolic disorder, which affects more than 171 million people worldwide. Diminished insulin secretion due to impaired cell function and or insulin resistance of the peripheral tissues such as liver, adipose tissue and skeletal muscle causes hyperglycemia, which is controlled with suitable pharmacological agents. The current line of treatment includes: (1) insulin secretagogues, (2) insulin sensitizers, (3) dipeptidyl peptidase IV inhibitors, (4) biguanides, (5) glucosidase inhibitors and (6) drugs in development.
Export Options
About this article
Cite this article as:
Zito W. S., Shinde J., Chen S. I C., Taldone T. and Barletta M., Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes, Current Bioactive Compounds 2008; 4 (2) . https://dx.doi.org/10.2174/157340708785294190
DOI https://dx.doi.org/10.2174/157340708785294190 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Literature Review on Diabetes Internet-based Spanish-Language Information
Current Diabetes Reviews Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Novel Biomarkers Assessing Endothelial Dysfunction: Role of microRNAs
Current Topics in Medicinal Chemistry Prediction and Diagnosis of Post Transplant Diabetes
Current Diabetes Reviews Medication Adherence of Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Considering the Psychosocial Factors, Health Literacy and Current Life Concerns of Patients
Current Rheumatology Reviews Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk
Current Molecular Pharmacology Antiepileptics and the Treatment of Neuropathic Pain: Evidence from Animal Models
Current Pharmaceutical Design Withdrawn: Alkaloidal Content, Medicinal, Properties of Peganum harmala L. (P. harmala)
Current Traditional Medicine Therapeutic Potential of Endothelial Progenitor Cells for Cardiovascular Diseases
Current Vascular Pharmacology Aldose Reductase, Oxidative Stress and Diabetic Cardiovascular Complications
Cardiovascular & Hematological Agents in Medicinal Chemistry Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice
Current Hypertension Reviews Assessment of the Aggregation Propensity of the β -amyloid Peptide During the Synthesis and when Free in Solution
Protein & Peptide Letters A proteomics based approach for the identification of gastric cancer related markers
Current Pharmaceutical Design The Efficacy of Psychological Therapies for Specific Phobias in Adults and Some Unanswered Questions
Current Psychiatry Reviews Bioactive Compounds in Diabetic Cardiomyopathy: Current Approaches and Potential Diagnostic and Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation
Current Vascular Pharmacology L-Arginine Transport in Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Botanical Therapeutics (Part II): Antimicrobial and In Vitro Anticancer Activity against MCF7 Human Breast Cancer Cells of Chamomile, Parsley and Celery Alcoholic Extracts
Anti-Cancer Agents in Medicinal Chemistry Treatment of Atherosclerotic Renovascular Disease
Current Hypertension Reviews